LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

Начало・Списък с акции・SCYNEXIS Inc

SCYNEXIS Inc

Затворен

0.7 -1.41

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.68

Максимум

0.73

Ключови измерители
By Trading Economics
Приходи	-1.7M -8.6M
Продажби	-1M 334K
Марж на печалбата	-2,572.156
Служители	28
EBITDA	9.4M -186K

Пазарни показатели
By TradingEconomics
Пазарна капитализация	5.5M 32M
Предишно отваряне	2.11
Предишно затваряне	0.7

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

0.9307 / 0.9907 Подкрепа & съпротива

SCYNEXIS Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.02.2026 г., 22:04 ч. UTC

Печалби

Coles 1st Half Net Profit Falls 11% on Worker Remediation Costs

26.02.2026 г., 23:55 ч. UTC

Пазарно говорене

Gold Edges Higher as Traders Digest U.S.-Iran Talks -- Market Talk

26.02.2026 г., 23:40 ч. UTC

Придобивния, сливания и поглъщания

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- Update

26.02.2026 г., 23:37 ч. UTC

Пазарно говорене

Japanese Stocks May Fall, Tracking Wall Street's Decline -- Market Talk

26.02.2026 г., 23:32 ч. UTC

Печалби

Why Nvidia's Huge Numbers Don't Settle the Latest AI Fears -- Heard on the Street -- WSJ

26.02.2026 г., 23:19 ч. UTC

Придобивния, сливания и поглъщания

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26.02.2026 г., 23:18 ч. UTC

Придобивния, сливания и поглъщания

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26.02.2026 г., 23:12 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Global Equities Roundup: Market Talk

26.02.2026 г., 23:12 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Netflix Gives Up in Bidding War Over Warner -- Market Talk

26.02.2026 г., 23:01 ч. UTC

Придобивния, сливания и поглъщания

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26.02.2026 г., 23:00 ч. UTC

Придобивния, сливания и поглъщания

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26.02.2026 г., 23:00 ч. UTC

Придобивния, сливания и поглъщания

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26.02.2026 г., 22:55 ч. UTC

Придобивния, сливания и поглъщания

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26.02.2026 г., 22:43 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

26.02.2026 г., 22:43 ч. UTC

Пазарно говорене

RBA Hike In March Is Being Underpriced -- Market Talk

26.02.2026 г., 22:33 ч. UTC

Придобивния, сливания и поглъщания

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26.02.2026 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26.02.2026 г., 22:13 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Bidding War Over Warner Bros. Set to Continue -- Market Talk

26.02.2026 г., 21:59 ч. UTC

Печалби

D-Wave Quantum Stock Rises on Earnings. Why a Revenue Miss Doesn't Seem to Matter. -- Barrons.com

26.02.2026 г., 21:58 ч. UTC

Придобивния, сливания и поглъщания

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

26.02.2026 г., 21:49 ч. UTC

Печалби

Coles 1H Net Profit Falls 11% on Worker Remediation Costs

26.02.2026 г., 21:45 ч. UTC

Печалби

Coles Expects One-Off Costs of Around A$7 Million in 1H to Complete Simplification Process

26.02.2026 г., 21:44 ч. UTC

Печалби

Coles Says Liquor Sales Fell 2.5% in First Seven Weeks of 3Q

26.02.2026 г., 21:44 ч. UTC

Печалби

Coles Expects Market to Remain Highly Competitive

26.02.2026 г., 21:44 ч. UTC

Печалби

Coles Says Supermarket Customers Remain Value Oriented

26.02.2026 г., 21:43 ч. UTC

Печалби

Coles Says Supermarket Sales Revenue Up 5.3% in First Seven Weeks of 3Q When Tobacco Excluded

26.02.2026 г., 21:43 ч. UTC

Печалби

Coles Says Supermarket Sales Revenue Up 3.7% in First Seven Weeks of 3Q

26.02.2026 г., 21:42 ч. UTC

Придобивния, сливания и поглъщания

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- WSJ

26.02.2026 г., 21:41 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Warner Bros. Earnings Report Falls Short. What It Means for the Netflix Takeover Saga. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

SCYNEXIS Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на SCYNEXIS Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.9307 / 0.9907Подкрепа & съпротива

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.